Skip to main content
OpenTrials
Completed

NCT Number: NCT04938440

Assessment of Updated Educational Materials for Instanyl®

The purpose of the Instanyl study is to learn how much doctors know and understand about Instanyl® before and after they receive updated educational information, including the risks of its unapproved use. In this study, the doctors will complete two surveys: one three months before they receive the updated educational information, and one about six months after they receive this information. They will answer questions about their prescribing behavior plus their knowledge of Instanyl® including any risks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pain Cancer Pain Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Central Contact

Cambridge, Massachusetts, 02142, United States

About this study

This is a non-interventional, observational, cross-sectional study of prescribers of Instanyl®.

This study will assess the prescribers' awareness of the updated EMs and changes in prescribers' knowledge and understanding of the key information contained in the updated EMs. The study will enroll approximately 259 prescribers. The first survey (pre-EM survey) will be conducted three months before the distribution of updated EMs, second survey (post-EM survey) will be conducted six months following the distribution of updated EMs.

The data will be collected, through a self-administered web-based questionnaire. All participants will be enrolled in a single observational group:

  • Prescriber of Instanyl®

This multi-center study will be conducted in France, the Netherlands, and Poland. The overall duration of the study will be approximately 22 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Specialists of any of those medical specialties targeted for the EMs as agreed with each national competent authority. The foreseen specialties include the following (subject to changes after the EM distribution plan is completed and agreed with national competent authorities):
  • Oncologists and oncoradiologists
  • Anaesthesiologists
  • Pain management prescribers
  • Palliative care prescribers
  • Internal medicine prescribers
  • General practitioner (GPs)
  • Other specialties may be locally included such as hematology. Current and potential prescribers may vary between country; thus, some countries may have modified lists of target specialties.
  • Physicians who have prescribed Instanyl® in the past 12 months (pre-EM survey) or since the updated EMs (post-EM survey) and who intend to prescribe Instanyl® in the following months after each survey.

Exclusion criteria

  • Physicians who may have a conflict of interest (that is, prescribers employed by regulatory bodies, pharmaceutical industries).
  • Inactive or retired prescribers.
  • Physicians who did not prescribe Instanyl® in the past 12 months (pre-EM survey) or since the updated EMs are distributed (post-EM survey) and do not foresee treating a participants with Instanyl® in the following 12 months, regardless of whether they have prescribed Instanyl® before.

Treatment and study plan

Primary outcomes

  1. Percentage of Prescribers With Awareness of Updated Educational Materials (EMs) Based on Post-EM Questionnaire Survey

    Time frame: Up to 6 months (Post-EM Survey)

  2. Percentage of Prescribers With Change in Knowledge and Understanding of Key Safety Information Contained in Updated EMs Based on Pre-EM to Post-EM Questionnaire Survey

    Time frame: Up to 9 months (Pre-EM to Post-EM survey)

  3. Percentage of Prescribers With Change in Self-Reported Behavior Prescribing Based on Pre-EM to Post-EM Questionnaire Survey

    Time frame: Up to 9 months (Pre-EM to Post-EM survey)

  4. Number of Reasons for Off-label Prescription

    Time frame: Up to 3 months (Pre-EM survey)

  5. Number of Prescribers With Awareness of the Profile of Patients at Risk of Misuse and Addiction

    Time frame: Up to 6 months (Post-EM Survey)

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Registry information

Official study title

Assessment of the Effectiveness of Updated Educational Materials on Prescribers' Knowledge and Behavior With Respect to Risks Associated With INSTANYL® Off-Label Use

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jun 24, 2021
Registry last updated
Aug 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.